Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ziarco Pharma Ltd
Sandwich, England, United Kingdomziarcopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead compound ZPL-389 (H4 receptor antagonist) showed clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score compared to placebo after eight weeks of treatment with a favorable safety profile
- Therapeutic areas
- NeurologyImmunologyDermatologyPulmonology
- Modalities
- Small moleculesoral and topical formulations
- Industry
- Biotech
02
Partnerships
Pfizer (licensed assets from Pfizer)
Beyond the preview
Go deeper on Ziarco Pharma Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ziarco Pharma Ltd.